295
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Gold nanoparticles as dose-enhancement agent for kilovoltage X-ray therapy of melanoma

&
Pages 517-526 | Received 01 Aug 2016, Accepted 08 Dec 2016, Published online: 23 Jan 2017
 

Abstract

Purpose: Melanoma is mainly treated by surgery and rarely with radiation because of the high radioresistance of this tumor. Nevertheless, radiotherapy is the preferred treatment modality for unresectable lesions and avoiding cosmetic disfigurement caused by surgical excision. This study investigated the therapeutic advantage of gold nanoparticles (AuNPs) for kilovoltage X-ray treatment of melanoma.

Materials and methods: Commercial AuNPs were evaluated for cytotoxicity and cellular internalization. The sensitivity of human skin melanoma cells to 150 and 450 kVp X-ray exposure was assessed in terms of clonogenicity with or without spherical AuNP treatment.

Results: AuNP treatment elicited dose enhancement effect on melanoma cells exposed to kilovoltage X-rays. Treatment with 320 μM 50 nm AuNPs before exposure to 150 kVp X-rays at 2 Gy resulted in clonogenic cell death equivalent to that caused by 4.3 Gy X-rays without AuNP treatment.

Conclusion: AuNPs of 50 nm in size can regulate melanoma cells in kilovoltage X-ray treatment by functioning as dose-enhancement agent and thus improving radioresponse of the cells. Melanomas of stages T1–T3 gain therapeutic benefits from 150 kVp X-ray treatment.

Disclosure statement

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

Additional information

Funding

This work was supported by Basic Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning [No. 2009-0067743].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.